• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种能够抑制同源补体跨膜通道表达的人红细胞膜蛋白的分离。

Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

作者信息

Zalman L S, Wood L M, Müller-Eberhard H J

出版信息

Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975-9. doi: 10.1073/pnas.83.18.6975.

DOI:10.1073/pnas.83.18.6975
PMID:2428045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC386634/
Abstract

Erythrocytes are poorly lysed by homologous complement, whereas they are readily lysed by heterologous complement. This phenomenon had been attributed to an interference by the cell surface with the action of complement components C8 and C9. To isolate the responsible membrane constituent, detergent-solubilized human erythrocyte (EH) membranes were subjected to affinity chromatography by using human C9-Sepharose. The isolated protein had a mass of 38 kDa and, incorporated into liposomes, was highly effective in inhibiting complement-mediated channel expression, including the C5b-8, membrane attack complex, and tubular polymer of C9 channels. Antibody produced to the 38-kDa protein caused a 20-fold increase in reactive lysis of EH by isolated C5b6, C7, C8, and C9. The antibody did not enhance C5b-7 uptake, but it affected C9 binding to the target cell membrane. Antibody to human decay-accelerating factor, used as a control, had no effect on reactive lysis of EH. Anti-38-kDa protein did not enhance the action on EH of C8 and C9 from other species, indicating that the action of this regulatory protein is species specific. It was therefore termed homologous restriction factor (HRF). Blood cells other than erythrocytes, such as polymorphonuclear leukocytes, also exhibited cell-surface HRF activity. In immunoblots of freshly isolated EH membranes, anti-38-kDa HRF detected primarily a 65-kDa protein, suggesting that the 38-kDa protein constitutes an active fragment of membrane HRF. Because of the specific binding reaction observed between HRF and C8 or C9, HRF was tested with anti-human C8 and anti-human C9. A limited immunochemical relationship of HRF to C8 and C9 could be established and solid-phase anti-C9 proved an efficient tool for the isolation of HRF from solubilized EH membranes.

摘要

红细胞不易被同源补体溶解,而异源补体则很容易使其溶解。这种现象被认为是细胞表面干扰了补体成分C8和C9的作用所致。为了分离出起作用的膜成分,用去污剂溶解的人红细胞(EH)膜通过人C9-琼脂糖亲和层析法进行分离。分离出的蛋白质分子量为38 kDa,将其掺入脂质体后,能高效抑制补体介导的通道表达,包括C5b-8、膜攻击复合物和C9通道的管状聚合物。针对38 kDa蛋白质产生的抗体使分离出的C5b6、C7、C8和C9对EH的反应性溶解增加了20倍。该抗体不会增强C5b-7的摄取,但会影响C9与靶细胞膜的结合。用作对照的人衰变加速因子抗体对EH的反应性溶解没有影响。抗38 kDa蛋白质不会增强其他物种的C8和C9对EH的作用,表明这种调节蛋白的作用具有物种特异性。因此,它被称为同源限制因子(HRF)。红细胞以外的血细胞,如多形核白细胞,也表现出细胞表面HRF活性。在新鲜分离的EH膜的免疫印迹中,抗38 kDa HRF主要检测到一种65 kDa的蛋白质,这表明38 kDa蛋白质构成了膜HRF的活性片段。由于观察到HRF与C8或C9之间存在特异性结合反应,因此用抗人C8和抗人C9对HRF进行了检测。可以确定HRF与C8和C9之间存在有限的免疫化学关系,并且固相抗C9被证明是从溶解的EH膜中分离HRF的有效工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/891a/386634/5038e7d3529c/pnas00322-0320-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/891a/386634/dcfa58eeb201/pnas00322-0320-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/891a/386634/5038e7d3529c/pnas00322-0320-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/891a/386634/dcfa58eeb201/pnas00322-0320-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/891a/386634/5038e7d3529c/pnas00322-0320-b.jpg

相似文献

1
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.一种能够抑制同源补体跨膜通道表达的人红细胞膜蛋白的分离。
Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975-9. doi: 10.1073/pnas.83.18.6975.
2
Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.同源限制因子:对补体C8和C9摄取及溶解的影响。
Mol Immunol. 1994 Mar;31(4):301-5. doi: 10.1016/0161-5890(94)90127-9.
3
Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.负责补体介导的细胞溶解的同源物种限制的膜因子:在C8和C9阶段起作用的除衰变加速因子(DAF)之外的一种因子的证据。
J Immunol. 1986 Mar 1;136(5):1777-82.
4
Anti-idiotypic antibodies derived against C8, C9 and perforin bind homologous restriction factor.针对C8、C9和穿孔素产生的抗独特型抗体可结合同源限制因子。
J Immunol Methods. 1990 Mar 27;128(1):133-42. doi: 10.1016/0022-1759(90)90472-8.
5
Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.人红细胞裂解中的同源物种限制:一种具有C8结合能力的膜衍生蛋白发挥抑制剂作用。
J Immunol. 1986 Mar 1;136(5):1772-6.
6
Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.CD59对同源补体的抑制作用是通过与C5b-8中的C8或C5b-9中的C9结合所赋予的物种选择性识别来介导的。
J Immunol. 1991 Apr 1;146(7):2345-51.
7
Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes.阵发性夜间血红蛋白尿红细胞的增强反应性溶解。关于C9结合及掺入高分子量复合物的研究。
J Exp Med. 1986 Oct 1;164(4):981-97. doi: 10.1084/jem.164.4.981.
8
Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.III型阵发性夜间血红蛋白尿。缺乏限制C5b-9介导红细胞溶解的红细胞膜蛋白。
J Clin Invest. 1987 Jul;80(1):7-12. doi: 10.1172/JCI113065.
9
The homologous restriction factor is immunologically related to complement components C8 and C9 and to lymphocyte pore-forming protein perforin through cysteine-rich domains.同源限制因子通过富含半胱氨酸的结构域与补体成分C8和C9以及淋巴细胞穿孔蛋白穿孔素在免疫学上相关。
Biochem Biophys Res Commun. 1990 Jan 30;166(2):648-52. doi: 10.1016/0006-291x(90)90858-k.
10
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly.补体膜攻击复合物中C9的分子组织。C5b-8组装诱导C9环状聚合。
J Exp Med. 1982 Jul 1;156(1):268-82. doi: 10.1084/jem.156.1.268.

引用本文的文献

1
Red blood cell extracellular vesicles: new frontiers in hematological biomarker discovery.红细胞细胞外囊泡:血液学生物标志物发现的新前沿。
Front Med (Lausanne). 2025 Aug 18;12:1644077. doi: 10.3389/fmed.2025.1644077. eCollection 2025.
2
The Prospect of Biomimetic Immune Cell Membrane-Coated Nanomedicines for Treatment of Serious Bacterial Infections and Sepsis.仿生免疫细胞膜包覆纳米药物治疗严重细菌感染和脓毒症的前景。
J Pharmacol Exp Ther. 2024 May 21;389(3):289-300. doi: 10.1124/jpet.123.002095.
3
Application of Nanomaterials in the Prevention, Detection, and Treatment of Methicillin-Resistant (MRSA).

本文引用的文献

1
Membrane attack complex of complement: a structural analysis of its assembly.补体膜攻击复合物:其组装的结构分析
J Exp Med. 1980 Feb 1;151(2):301-13. doi: 10.1084/jem.151.2.301.
2
Homologous species restriction in lysis of erythrocytes by terminal complement proteins.终末补体蛋白对红细胞溶解的同源物种限制
Proc Natl Acad Sci U S A. 1981 Aug;78(8):5118-21. doi: 10.1073/pnas.78.8.5118.
3
Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells.
纳米材料在耐甲氧西林金黄色葡萄球菌(MRSA)预防、检测及治疗中的应用
Pharmaceutics. 2022 Apr 6;14(4):805. doi: 10.3390/pharmaceutics14040805.
4
Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities.基于红细胞细胞外囊泡的药物递送:挑战与机遇
Front Med (Lausanne). 2021 Dec 24;8:761362. doi: 10.3389/fmed.2021.761362. eCollection 2021.
5
Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.红细胞:一个被忽视的载体向人工纳米载体天然母舰的蜕变。
Adv Drug Deliv Rev. 2021 Nov;178:113992. doi: 10.1016/j.addr.2021.113992. Epub 2021 Sep 29.
6
Extracellular Vesicles from Red Blood Cells and Their Evolving Roles in Health, Coagulopathy and Therapy.红细胞来源的细胞外囊泡及其在健康、凝血病和治疗中的演变作用。
Int J Mol Sci. 2020 Dec 25;22(1):153. doi: 10.3390/ijms22010153.
7
Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical Applications.人羊膜上皮干细胞:一种有前途的临床应用种子细胞。
Int J Mol Sci. 2020 Oct 19;21(20):7730. doi: 10.3390/ijms21207730.
8
Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application.红细胞膜伪装纳米颗粒:一种用于抗肿瘤应用的新型药物递送系统。
Acta Pharm Sin B. 2019 Jul;9(4):675-689. doi: 10.1016/j.apsb.2019.01.011. Epub 2019 Jan 24.
9
Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment.载有藤黄酸的仿生纳米颗粒用于结直肠癌治疗
Int J Nanomedicine. 2017 Feb 28;12:1593-1605. doi: 10.2147/IJN.S127256. eCollection 2017.
10
Killing machines: three pore-forming proteins of the immune system.杀伤机器:免疫系统的三种孔形成蛋白。
Immunol Res. 2013 Dec;57(1-3):268-78. doi: 10.1007/s12026-013-8469-9.
人红细胞的补体溶解作用。III. 人及豚鼠C9对正常和阵发性夜间血红蛋白尿细胞的不同作用效果
J Immunol. 1980 Nov;125(5):2063-8.
4
The ninth component of human complement: purification and physicochemical characterization.人类补体的第九成分:纯化及理化特性分析
J Immunol. 1980 Mar;124(3):1291-6.
5
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.阵发性夜间血红蛋白尿患者的受累红细胞缺乏补体调节蛋白衰变加速因子。
Proc Natl Acad Sci U S A. 1983 Aug;80(16):5066-70. doi: 10.1073/pnas.80.16.5066.
6
Specificity of diffusion channels produced by lambda phage receptor protein of Escherichia coli.大肠杆菌λ噬菌体受体蛋白产生的扩散通道的特异性
Proc Natl Acad Sci U S A. 1980 Jan;77(1):167-71. doi: 10.1073/pnas.77.1.167.
7
Circular polymerization of the membranolytic ninth component of complement. Dependence on metal ions.补体膜溶解第九成分的环状聚合。对金属离子的依赖性。
J Biol Chem. 1984 Aug 25;259(16):10569-73.
8
Mechanism of insertion of diphtheria toxin: peptide entry and pore size determinations.白喉毒素的插入机制:肽进入和孔径测定
Proc Natl Acad Sci U S A. 1984 Jun;81(11):3341-5. doi: 10.1073/pnas.81.11.3341.
9
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.衰变加速因子(DAF)整合到细胞膜后对细胞表面补体激活的抑制作用。
J Exp Med. 1984 Nov 1;160(5):1558-78. doi: 10.1084/jem.160.5.1558.
10
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.阵发性夜间血红蛋白尿中具有补体调节活性的红细胞膜蛋白缺乏。
Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430-4. doi: 10.1073/pnas.80.17.5430.